C4 Therapeutics (CCCC) Analyst & Key Data

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

10

Hold

3

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score1.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$3.51

Median Target+118.52%

$7.67

Potential upside vs current price

DCF Value-177.13%

-$2.71

Potential downside vs current price

Current Stock Price

$3.51

Median Target+118.52%

$7.67

Potential upside vs current price

DCF Value-177.13%

-$2.71

Potential downside vs current price

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

10

Hold

3

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score1.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$3.51

Median Target+118.52%

$7.67

Potential upside vs current price

DCF Value-177.13%

-$2.71

Potential downside vs current price

Current Stock Price

$3.51

Median Target+118.52%

$7.67

Potential upside vs current price

DCF Value-177.13%

-$2.71

Potential downside vs current price

C4 Therapeutics, Inc.